603 related articles for article (PubMed ID: 16784126)
41. [Onychomycosis-causing yeasts in four Mexican dermatology centers and their antifungal susceptibility to azolic compounds].
Manzano-Gayosso P; Méndez-Tovar LJ; Arenas R; Hernández-Hernández F; Millán-Chiu B; Torres-Rodríguez JM; Cortés-González E; Fernández R; López-Martínez R
Rev Iberoam Micol; 2011; 28(1):32-5. PubMed ID: 21147249
[TBL] [Abstract][Full Text] [Related]
42. Antifungal susceptibilities of Candida species isolated from the patients with vaginal candidiasis.
Nagashima M; Yamagishi Y; Mikamo H
J Infect Chemother; 2016 Feb; 22(2):124-6. PubMed ID: 26627336
[TBL] [Abstract][Full Text] [Related]
43. Prevalence of Candida albicans-closely related yeasts, Candida africana and Candida dubliniensis, in vulvovaginal candidiasis.
Shan Y; Fan S; Liu X; Li J
Med Mycol; 2014 Aug; 52(6):636-40. PubMed ID: 25023482
[TBL] [Abstract][Full Text] [Related]
44. Guideline vulvovaginal candidosis (2010) of the German Society for Gynecology and Obstetrics, the Working Group for Infections and Infectimmunology in Gynecology and Obstetrics, the German Society of Dermatology, the Board of German Dermatologists and the German Speaking Mycological Society.
Mendling W; Brasch J; ; ; ;
Mycoses; 2012 Jul; 55 Suppl 3():1-13. PubMed ID: 22519657
[TBL] [Abstract][Full Text] [Related]
45. Prevalence of Candida albicans, Candida dubliniensis and Candida africana in pregnant women suffering from vulvovaginal candidiasis in Argentina.
Mucci MJ; Cuestas ML; Landanburu MF; Mujica MT
Rev Iberoam Micol; 2017; 34(2):72-76. PubMed ID: 28385421
[TBL] [Abstract][Full Text] [Related]
46. Epidemiology and antifungal susceptibilities of Candida spp. to six antifungal agents: results from a surveillance study on fungaemia in Germany from July 2004 to August 2005.
Borg-von Zepelin M; Kunz L; Rüchel R; Reichard U; Weig M; Gross U
J Antimicrob Chemother; 2007 Aug; 60(2):424-8. PubMed ID: 17562683
[TBL] [Abstract][Full Text] [Related]
47. Prevalence and antifungal resistance profile of Candida spp. oral isolates from patients with type 1 and 2 diabetes mellitus.
Bremenkamp RM; Caris AR; Jorge AO; Back-Brito GN; Mota AJ; Balducci I; Brighenti FL; Koga-Ito CY
Arch Oral Biol; 2011 Jun; 56(6):549-55. PubMed ID: 21183157
[TBL] [Abstract][Full Text] [Related]
48. Prevalence and antifungal susceptibility of Candida albicans and its related species Candida dubliniensis and Candida africana isolated from vulvovaginal samples in a hospital of Argentina.
Theill L; Dudiuk C; Morano S; Gamarra S; Nardin ME; Méndez E; Garcia-Effron G
Rev Argent Microbiol; 2016; 48(1):43-9. PubMed ID: 26922471
[TBL] [Abstract][Full Text] [Related]
49. Antifungal resistance in Candida spp. isolated in Italy between 2002 and 2005 from children and adults.
Gualco L; Debbia EA; Bandettini R; Pescetto L; Cavallero A; Ossi MC; Schito AM; Marchese A
Int J Antimicrob Agents; 2007 Feb; 29(2):179-84. PubMed ID: 17175140
[TBL] [Abstract][Full Text] [Related]
50. [Rapid identification and susceptibility to killer toxins of yeasts isolated from non-systemic mycoses].
Sangorrín MP; Lopes CA; Rivero A; Caballero AC
Rev Argent Microbiol; 2007; 39(4):230-6. PubMed ID: 18390160
[TBL] [Abstract][Full Text] [Related]
51. Prevalence and management of non-albicans vaginal candidiasis.
Hettiarachchi N; Ashbee HR; Wilson JD
Sex Transm Infect; 2010 Apr; 86(2):99-100. PubMed ID: 20332368
[TBL] [Abstract][Full Text] [Related]
52. Epidemiology and antifungal susceptibility patterns of Candida isolates from Greek women with vulvovaginal candidiasis.
Maraki S; Mavromanolaki VE; Stafylaki D; Nioti E; Hamilos G; Kasimati A
Mycoses; 2019 Aug; 62(8):692-697. PubMed ID: 31132175
[TBL] [Abstract][Full Text] [Related]
53. Prevalence of vulvovaginal candidiasis in pregnancy at three health centers in Burkina Faso.
Sangaré I; Sirima C; Bamba S; Zida A; Cissé M; Bazié WW; Sanou S; Dao B; Menan H; Guiguemdé RT
J Mycol Med; 2018 Mar; 28(1):186-192. PubMed ID: 28939305
[TBL] [Abstract][Full Text] [Related]
54. Susceptibility of candida isolates from denture-related stomatitis to antifungal agents in vitro.
Dorocka-Bobkowska B; Konopka K
Int J Prosthodont; 2007; 20(5):504-6. PubMed ID: 17944341
[TBL] [Abstract][Full Text] [Related]
55. Susceptibility patterns of Candida species recovered from Canadian intensive care units.
Laverdiere M; Labbé AC; Restieri C; Rotstein C; Heyland D; Madger S; Stewart T
J Crit Care; 2007 Sep; 22(3):245-50. PubMed ID: 17869976
[TBL] [Abstract][Full Text] [Related]
56. [Isolation frequency and spectrum of sensitivity to antifungal preparations of vulvovaginal candidiasis pathogens].
Skliar TV; Krysenko AV; Sirokvasha EA; Vinnikov AI
Mikrobiol Z; 2007; 69(3):57-62. PubMed ID: 17682532
[TBL] [Abstract][Full Text] [Related]
57. Prevalence of Candida species in different hospital wards and their susceptibility to antifungal agents: results of a three year survey.
Fadda ME; Podda GS; Pisano MB; Deplano M; Cosentino S
J Prev Med Hyg; 2008 Jun; 49(2):69-74. PubMed ID: 18847180
[TBL] [Abstract][Full Text] [Related]
58. In vitro fluconazole and nystatin susceptibility and clinical outcome in complicated vulvovaginal candidosis.
Fan SR; Liu XP
Mycoses; 2011 Nov; 54(6):501-5. PubMed ID: 20406393
[TBL] [Abstract][Full Text] [Related]
59. In vitro susceptibility of Candida species to five antifungal agents in a German university hospital assessed by the reference broth microdilution method and Etest.
Fleck R; Dietz A; Hof H
J Antimicrob Chemother; 2007 Apr; 59(4):767-71. PubMed ID: 17293369
[TBL] [Abstract][Full Text] [Related]
60. [Vulvovaginal candidiasis and sensitivity of pathogens to antimycotics].
Sojáková M; Liptajová D; Simoncicová M; Borovský M; Subík J
Ceska Gynekol; 2003 Jan; 68(1):24-9. PubMed ID: 12708111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
